Advancements in gene therapy and personalised medicine continue to revolutionize healthcare, leading to the potential of many new cutting edge treatments and therapies. However, ensuring compliance with regulatory standards and addressing ethical concerns is becoming increasing critical. This field holds immense potential for innovative technologies, such as CRISPR gene editing technologies, but it also raises important questions about patient consent, risks of long-term effects and ethical dilemma in human genetic modification. In this panel, we will look at the potential that gene therapy and personalised medicine hold both from a medical and economic perspective, and consider the associated risks, and ethical and compliance challenges. The panel will consider how regulations can evolve to safeguard patients while fostering innovation, and shaping the future of medicine